Biota, Inc.

**What if the key to safer communities and a healthier planet could be found in our wastewater?** Biota is a VC-backed startup on a mission to transform wastewater into actionable insights that make our communities safer and more sustainable. Our focus is on revolutionizing the way wastewater utilities monitor and source track PFAS (per- and polyfluoroalkyl substances), also known as “forever chemicals.” In April 2024, the EPA classified PFAS compounds as toxic, linking them to severe health issues such as liver cancer, infertility, and developmental delays. These chemicals are pervasive in our food, water, and environment, creating an urgent need for innovative monitoring solutions. Biota adapts proven diagnostic technologies from the healthcare industry to meet the needs of wastewater utilities. Our platform provides the first rapid, point-of-care analytics solution for onsite wastewater testing, addressing a critical gap in the industry. By enabling utilities to comply with new EPA regulations quickly and effectively, Biota is paving the way for safer water systems and, in the future, unlocking wastewater’s potential to monitor broader human behaviors—such as tracking viruses, illicit drugs, and industrial pollution. Why Biota: • First-of-its-kind solution: Rapid, point-of-care diagnostic platform for wastewater testing. • Massive market opportunity: Addressing a $4 billion+ annual market. • Strong momentum: Supported by a talented team and driving compliance with new EPA PFAS regulations. • Early traction: Biota graduated from the Antler Founder Residency and immediately raised an oversubscribed pre-seed round from investors spanning two key sectors: biotech and water tech. At Biota, we’re committed to innovation that safeguards public health and advances environmental sustainability, one sample at a time.

Industry

Public Health

Company size

2-10 employees

Headquarters

Boulder, CO

Type

Privately Held

Founded

2024

Specialties

wastewater, rapid testing, environmental testing, data science, and biotechnology